Anis Askarizadeh

436 total citations
17 papers, 322 citations indexed

About

Anis Askarizadeh is a scholar working on Biomaterials, Biomedical Engineering and Molecular Biology. According to data from OpenAlex, Anis Askarizadeh has authored 17 papers receiving a total of 322 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Biomaterials, 8 papers in Biomedical Engineering and 5 papers in Molecular Biology. Recurrent topics in Anis Askarizadeh's work include Nanoparticle-Based Drug Delivery (13 papers), Nanoplatforms for cancer theranostics (7 papers) and RNA Interference and Gene Delivery (4 papers). Anis Askarizadeh is often cited by papers focused on Nanoparticle-Based Drug Delivery (13 papers), Nanoplatforms for cancer theranostics (7 papers) and RNA Interference and Gene Delivery (4 papers). Anis Askarizadeh collaborates with scholars based in Iran, United Kingdom and Chile. Anis Askarizadeh's co-authors include Ali Badiee, Mahmoud Reza Jaafari, Amirhossein Sahebkar, Mohammad Mashreghi, Elaheh Mirhadi, George E. Barreto, Muhammed Majeed, Leila Arabi, Seyedeh Hoda Alavizadeh and Amin Mehrabian and has published in prestigious journals such as Scientific Reports, International Journal of Pharmaceutics and Life Sciences.

In The Last Decade

Anis Askarizadeh

17 papers receiving 319 citations

Peers

Anis Askarizadeh

BIOMA

ONCOL

Mahdie Hemati Iran

Ziyi Hu China

Shweta Dumoga India

Khaled Abou‐Aisha Egypt

Xiaoyi Zheng China

Sara Nikoofal‐Sahlabadi Iran

Adem Şahin Türkiye

Mohsen Asouri Iran

Mohammad Sameer Khan India

Zhengjie Meng China

Mahdie Hemati Iran

Anis Askarizadeh

118 ×0.9

BIOMA

167 ×1.4

90 ×0.9

35 ×0.9

22 ×0.7

ONCOL

Citations per year, relative to Anis Askarizadeh Anis Askarizadeh (= 1×) peers Mahdie Hemati

Countries citing papers authored by Anis Askarizadeh

Since Specialization

Citations

This map shows the geographic impact of Anis Askarizadeh's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Anis Askarizadeh with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Anis Askarizadeh more than expected).

Fields of papers citing papers by Anis Askarizadeh

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Anis Askarizadeh. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Anis Askarizadeh. The network helps show where Anis Askarizadeh may publish in the future.

Co-authorship network of co-authors of Anis Askarizadeh

This figure shows the co-authorship network connecting the top 25 collaborators of Anis Askarizadeh. A scholar is included among the top collaborators of Anis Askarizadeh based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Anis Askarizadeh. Anis Askarizadeh is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

17 of 17 papers shown

Kazemi‐Beydokhti, Amin, Elaheh Mirhadi, Fatemeh Gheybi, et al.. (2024). Engineered hybrid carbon nanohorns-lipid platforms for the delivery of cisplatin to the colorectal cancer. Journal of Drug Delivery Science and Technology. 100. 106101–106101. 2 indexed citations

Mirhadi, Elaheh, et al.. (2024). Liposomal delivery of organoselenium-cisplatin complex as a novel therapeutic approach for colon cancer therapy. Colloids and Surfaces B Biointerfaces. 242. 114085–114085. 7 indexed citations

Askarizadeh, Anis, et al.. (2024). Lipid nanoparticle-based delivery of small interfering RNAs: New possibilities in the treatment of diverse diseases. European Polymer Journal. 223. 113624–113624. 3 indexed citations

Mirhadi, Elaheh, Anis Askarizadeh, Mohammad Mashreghi, et al.. (2024). The impact of phospholipids with high transition temperature to enhance redox-sensitive liposomal doxorubicin efficacy in colon carcinoma model. Chemistry and Physics of Lipids. 261. 105396–105396. 7 indexed citations

Askarizadeh, Anis, Mohammad Mashreghi, Elaheh Mirhadi, et al.. (2023). Doxorubicin-loaded liposomes surface engineered with the matrix metalloproteinase-2 cleavable polyethylene glycol conjugate for cancer therapy. Cancer Nanotechnology. 14(1). 18–18. 36 indexed citations

Mehrabian, Amin, Mohammad Mashreghi, Anis Askarizadeh, et al.. (2023). The comparison of biodistribution of glutathione PEGylated nanoliposomal doxorubicin formulations prepared by pre‐insertion and post‐insertion methods for brain delivery in normal mice. IET Nanobiotechnology. 17(2). 112–124. 13 indexed citations

Arabi, Leila, Mehdi Montazer, Anis Askarizadeh, et al.. (2023). The effect of m2 peptide targeted nanoliposomes containing crocin on induction of phenotypic change in tumor macrophages to M1 state. Life Sciences. 330. 121992–121992. 5 indexed citations

Askarizadeh, Anis, Mohammad Mashreghi, Elaheh Mirhadi, et al.. (2023). Surface-modified cationic liposomes with a matrix metalloproteinase-degradable polyethylene glycol derivative improved doxorubicin delivery in murine colon cancer. Journal of Liposome Research. 34(2). 221–238. 6 indexed citations

Mirhadi, Elaheh, Fatemeh Gheybi, Anis Askarizadeh, et al.. (2022). Amino acid coordination complex mediates cisplatin entrapment within PEGylated liposome: An implication in colorectal cancer therapy. International Journal of Pharmaceutics. 623. 121946–121946. 10 indexed citations

10.

Mashreghi, Mohammad, Mahdi Faal Maleki, Anis Askarizadeh, et al.. (2022). A novel and easy to prepare azo-based bioreductive linker and its application in hypoxia-sensitive cationic liposomal doxorubicin: Synthesis, characterization, in vitro and in vivo studies in mice bearing C26 tumor. Chemistry and Physics of Lipids. 247. 105226–105226. 7 indexed citations

11.

Mirhadi, Elaheh, Mohammad Mashreghi, Anis Askarizadeh, et al.. (2022). Redox-sensitive doxorubicin liposome: a formulation approach for targeted tumor therapy. Scientific Reports. 12(1). 11310–11310. 33 indexed citations

12.

Mehrabian, Amin, et al.. (2022). The role of size in PEGylated liposomal doxorubicin biodistribution and anti‐tumour activity. IET Nanobiotechnology. 16(7-8). 259–272. 25 indexed citations

13.

Askarizadeh, Anis, et al.. (2020). Neuroprotection by curcumin: A review on brain delivery strategies. International Journal of Pharmaceutics. 585. 119476–119476. 76 indexed citations

14.

Askarizadeh, Anis, Ali Badiee, & Ali Khamesipour. (2020). Development of nano-carriers forLeishmaniavaccine delivery. Expert Opinion on Drug Delivery. 17(2). 167–187. 17 indexed citations

15.

Maleki, Mahdi Faal, Elaheh Mirhadi, Anis Askarizadeh, et al.. (2019). Endogenous stimuli-responsive linkers in nanoliposomal systems for cancer drug targeting. International Journal of Pharmaceutics. 572. 118716–118716. 32 indexed citations

16.

Askarizadeh, Anis, Alexandra E. Butler, Ali Badiee, & Amirhossein Sahebkar. (2018). Liposomal nanocarriers for statins: A pharmacokinetic and pharmacodynamics appraisal. Journal of Cellular Physiology. 234(2). 1219–1229. 25 indexed citations

17.

Askarizadeh, Anis, Mahmoud Reza Jaafari, Ali Khamesipour, & Ali Badiee. (2017). Liposomal adjuvant development for leishmaniasis vaccines. PubMed. 5(4-5). 85–101. 18 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact